Unified Approach Could Prevent Unnecessary Blood Tests in PICU without Increasing Sepsis Risk
|
By LabMedica International staff writers Posted on 03 May 2022 |

When a patient in the pediatric intensive care unit (PICU) develops a fever, physicians often routinely order a blood culture to identify the cause, particularly if they have reason to worry about sepsis, a life-threatening condition that occurs when chemicals released by immune system cells in the bloodstream to fight an infection trigger inflammation and shock throughout the body. However, repeated blood draws along with the use of antibiotics while awaiting culture results contribute to a rise in antibiotic resistance, leading to additional testing and extending the hospital length of stay. Now, researchers have developed and demonstrated the safety of a decision support program that appears to substantially reduce the number of blood draws in the PICU, and is likely to reduce antibiotic prescriptions without increasing the risk of sepsis.
The new study which was a national collaborative of 14 institutions and their experts, including researchers at Johns Hopkins University (Baltimore, MD, USA), builds on programs already in place that have safely reduced the use of other diagnostic tests, such as urine cultures. According to data from the U.S. Centers for Disease Control and Prevention, about 30% of antibiotics used in hospitals are unnecessary or prescribed incorrectly. Previous studies from other researchers have found that more than half of patients in the PICU often receive antibiotics for symptoms such as fever that may arise from noninfectious illnesses or even weaning from some medications.
In their study, the research team at Johns Hopkins Children’s Center led a national multidisciplinary collaborative of experts in pediatric infectious diseases, critical care medicine, quality improvement and other fields called BrighT STAR (Testing STewardship to reduce Antibiotic Resistance). The goal was to explore and compare existing studies and practices, and produce guidance recommendations to reduce blood draws in patients with low suspicion or risk for sepsis, and to measure the impact of the algorithm on blood culture rates, broad-spectrum antibiotic use and other patient outcomes. The 14 participating sites were diverse with respect to institution size, patient population and geographic area. Johns Hopkins Medicine investigators provided each site, which had its own team of experts, with a pre-implementation assessment tool while coaching them to launch their own quality improvement programs and strategies to execute the plans.
While the composition of the clinical support tools varied, each institution sought to standardize practices across its unit and reduce variability in decisions in ordering blood cultures, as well as highlight patient safety considerations. Blood culture rates, along with other measures, were tracked and reported monthly. The coordinating team held regular calls with individual sites and the larger collaborative throughout all steps of the project, conducted between 2017 and 2020.
In the 24-month period prior to implementation of the quality improvement algorithms, 41,731 blood cultures were performed at all 14 sites, compared with 22,408 cultures in the 18-month post-implementation period. Across sites, the median blood culture rate dropped from 146 per 1,000 patient days/month before implementation to 99 per 1,000 patient days/month after. Overall, 13 of 14 sites reduced their blood culture rates in the post-implementation period between 15% and 58%. Across the 14 sites, the blood culture rate was reduced by an average of 34% between the study’s pre- and post-implementation time frames (156.9 blood cultures per 1,000 patient days/month to 104.1 blood cultures per 1,000 patient days/month).
In the 11 sites that reported on antibiotic use, results showed a 13% overall average reduction in the amount of antibiotics prescribed (506.0 versus 440.3 total days per 1,000 patient days/month). At all 14 sites, central line-associated bloodstream infections decreased by 36% (1.79 to 1.14 per 1,000 central line days/month). There was no significant change in the rates of one of the most frequent and dangerous hospital-acquired infections, Clostridioides difficile (0.38 vs. 0.36 infections per 1,000 patient days/month). Mortality rates, length of stay and readmission in the PICU, as well as overall hospital readmissions, were similar before and after program implementation.
The research team has cautioned that the study may have missed instances in which antibiotics were prescribed without collecting blood cultures, which could have increased the amount prescribed. Also, all sites enrolled in the study had clinicians and others experienced in quality improvement. The researchers additionally say their analyses do not account for variations in individual site implementation plans. However, they believe their concept will help change clinician decision-making and, ultimately, benefit patients. The researchers are seeking to expand and implement a similar approach at all hospitals across the nation. They are also investigating ways to scale this concept to other hospital units, including those caring for adults.
“These findings suggest that multidisciplinary efforts to standardize blood culture collection and avoid unnecessary testing in the PICU can be done successfully and safely in diverse settings, and that reducing blood culture use can, in turn, reduce broad-spectrum antibiotic use,” said pediatric infectious diseases specialist Aaron Milstone, M.D., M.H.S., who is also a professor of pediatrics at the Johns Hopkins University School of Medicine and an expert on systems designed to prevent hospital-acquired infections and improve patient safety.
Related Links:
Johns Hopkins University
Latest Critical Care News
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more






 Analyzer.jpg)
